SES
15.5.2019 08:57:05 CEST | Business Wire | Press release
Dream Cruises, a brand of Genting Cruise Lines, has selected SES Networks’ Signature Cruise Solution to provide exceptional speeds, low latency, and unmatched fibre-like service to its passenger ship fleet, comprised of World Dream, Genting Dream and Explorer Dream, for the Asian luxury market, SES announced today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005969/en/
Crew and guests of the newly-launched Explorer Dream will experience exceptional SES-powered guest connectivity onboard the 75,000-gross-ton, 2,000-passenger ship. The SES Networks’ solution will also be introduced onboard Genting Dream in September this year, completing the fleet-wide implementation that follows the successful launch of SES Networks’ managed service onboard World Dream, Dream Cruises’ second cruise ship, which debuted in 2017.
The new Explorer Dream will have homeports in Shanghai and Tianjin, as well as Sydney and Auckland later in the year. Its significantly enhanced connectivity will enable guests to chat with friends on WeChat, pick up a bargain on Taobao, or stream high-resolution video on YouKu without interruption or lag. It will also mean that guests can share photos and videos from their trip in real-time across social media, or battle with their friends in League of Legends as easily as they can on land.
SES Networks’ Signature Cruise Solution combines the low latency of its O3b medium earth orbit (MEO) satellite constellation with a fully managed end-to-end service, backed up by its highly reliable geostationary (GEO) fleet to ensure network resilience. The result is a seamless, high-performance broadband service delivered to everyone onboard the Dream Cruises fleet.
“Today’s cruise passengers demand excellent connectivity even when they are travelling on the high seas. As part of our efforts to provide our guests with the best possible services and amenities on board our ships, we partnered with SES Networks because of their high-speed capability to deliver a terrestrial broadband-like internet experience in some of the most challenging of conditions,” said Thatcher Brown, President at Dream Cruises.
"A Dream Cruise has the ability to deliver inspirational voyages at sea that create memories to last a lifetime. A key part of that adventure nowadays is the digital experience. Our Signature Cruise Solution ensures that passengers onboard Explorer Dream – along with World Dream and Genting Dream – will experience the new standard of enhanced guest connectivity,” said Simon Maher, Vice President Global Sales, Cruise Maritime Services at SES Networks. “Because SES Networks and Dream Cruises have shared values around delivering transformational and inspirational experiences at sea, we are incredibly proud to partner with them to enable this level of service.”
Follow us on:
Social
Media
Blog
Media
Gallery
White
Papers
About SES
SES is the world’s leading satellite operator with over 70 satellites in two different orbits, Geostationary Orbit (GEO) and Medium Earth Orbit (MEO). It provides a diverse range of customers with global video distribution and data connectivity services through two business units: SES Video and SES Networks. SES Video reaches over 355 million TV homes, through Direct-to-Home (DTH) platforms and cable, terrestrial, and IPTV networks globally. The SES Video portfolio includes MX1, a leading media service provider offering a full suite of innovative services for both linear and digital distribution, and the ASTRA satellite system, which has the largest DTH television reach in Europe. SES Networks provides global managed data services, connecting people in a variety of sectors including telecommunications, maritime, aeronautical, and energy, as well as governments and institutions across the world. The SES Networks portfolio includes GovSat, a 50/50 public-private partnership between SES and the Luxembourg government, and O3b, the only non-geostationary system delivering fibre-like broadband services today. Further information is available at: www.ses.com
About Genting Cruise Lines
Genting Cruise Lines is a division of Genting Hong Kong comprising of three distinct cruise brands – Star Cruises, Dream Cruises and Crystal Cruises – providing a range of products from contemporary cruises to ultra-luxurious vacation experiences spanning the sea to air.
Established in 1993, Star Cruises is the pioneer in the Asia Pacific cruise industry currently with a fleet of six ships catering to the contemporary market segment. As “The Most Popular Cruise Line in Asia”, Star Cruises will further expand its footprint in the region with the delivery of two new “Global Class” ships, each measuring 201,000 gross tons, in 2020 and 2021.
“Asia’s Luxury Cruise Line”, Dream Cruises delivers the highest level of guest service and spacious comfort in the region via newly launched Genting Dream (November 2016) and the upcoming World Dream (late 2017). Developed for the high-end consumers in China and Asia, Dream Cruises will provide passengers with more choice, comfort and value to create a perfect dream voyage.
Crystal Cruises is “The World’s Most Awarded Luxury Cruise Line”, having earned more “World’s Best” awards than any other cruise line, hotel, or resort in history. Recently, Crystal has embarked on a significant brand expansion introducing two new classes of cruising – Crystal Yacht Cruises and Crystal River Cruises – and reaching new heights with Crystal Luxury Air and Crystal AirCruises.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005969/en/
Contact:
Suzanne Ong Public Relations Tel. +352 710 725 500 suzanne.ong@ses.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom